Standard
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3) : The NORDIC NEC study. / Sorbye, H; Welin, S; Langer, S W; Vestermark, L W; Holt, N; Osterlund, P; Dueland, S; Hofsli, E; Guren, M G; Ohrling, K; Birkemeyer, E; Thiis-Evensen, E; Biagini, Matteo; Gronbaek, H; Soveri, L M; Olsen, I H; Federspiel, B; Assmus, J; Janson, E T; Knigge, U.
In:
Annals of Oncology, Vol. 24, No. 1, 2013, p. 152-60.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Sorbye, H, Welin, S
, Langer, SW, Vestermark, LW, Holt, N, Osterlund, P, Dueland, S, Hofsli, E, Guren, MG, Ohrling, K, Birkemeyer, E, Thiis-Evensen, E, Biagini, M, Gronbaek, H, Soveri, LM, Olsen, IH, Federspiel, B, Assmus, J, Janson, ET
& Knigge, U 2013, '
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study',
Annals of Oncology, vol. 24, no. 1, pp. 152-60.
https://doi.org/10.1093/annonc/mds276
APA
Sorbye, H., Welin, S.
, Langer, S. W., Vestermark, L. W., Holt, N., Osterlund, P., Dueland, S., Hofsli, E., Guren, M. G., Ohrling, K., Birkemeyer, E., Thiis-Evensen, E., Biagini, M., Gronbaek, H., Soveri, L. M., Olsen, I. H., Federspiel, B., Assmus, J., Janson, E. T.
, & Knigge, U. (2013).
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study.
Annals of Oncology,
24(1), 152-60.
https://doi.org/10.1093/annonc/mds276
Vancouver
Sorbye H, Welin S
, Langer SW, Vestermark LW, Holt N, Osterlund P et al.
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study.
Annals of Oncology. 2013;24(1):152-60.
https://doi.org/10.1093/annonc/mds276
Author
Sorbye, H ; Welin, S ; Langer, S W ; Vestermark, L W ; Holt, N ; Osterlund, P ; Dueland, S ; Hofsli, E ; Guren, M G ; Ohrling, K ; Birkemeyer, E ; Thiis-Evensen, E ; Biagini, Matteo ; Gronbaek, H ; Soveri, L M ; Olsen, I H ; Federspiel, B ; Assmus, J ; Janson, E T ; Knigge, U. / Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3) : The NORDIC NEC study. In: Annals of Oncology. 2013 ; Vol. 24, No. 1. pp. 152-60.
Bibtex
@article{cd1851c7f1aa4d45aa4baf84a19f1119,
title = "Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study",
abstract = "Background As studies on gastrointestinal neuroendocrine carcinoma (WHO G3) (GI-NEC) are limited, we reviewed clinical data to identify predictive and prognostic markers for advanced GI-NEC patients. Patients and methods Data from advanced GI-NEC patients diagnosed 2000-2009 were retrospectively registered at 12 Nordic hospitals. Results The median survival was 11 months in 252 patients given palliative chemotherapy and 1 month in 53 patients receiving best supportive care (BSC) only. The response rate to first-line chemotherapy was 31% and 33% had stable disease. Ki-67 ",
author = "H Sorbye and S Welin and Langer, {S W} and Vestermark, {L W} and N Holt and P Osterlund and S Dueland and E Hofsli and Guren, {M G} and K Ohrling and E Birkemeyer and E Thiis-Evensen and Matteo Biagini and H Gronbaek and Soveri, {L M} and Olsen, {I H} and B Federspiel and J Assmus and Janson, {E T} and U Knigge",
year = "2013",
doi = "10.1093/annonc/mds276",
language = "English",
volume = "24",
pages = "152--60",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "1",
}
RIS
TY - JOUR
T1 - Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3)
T2 - The NORDIC NEC study
AU - Sorbye, H
AU - Welin, S
AU - Langer, S W
AU - Vestermark, L W
AU - Holt, N
AU - Osterlund, P
AU - Dueland, S
AU - Hofsli, E
AU - Guren, M G
AU - Ohrling, K
AU - Birkemeyer, E
AU - Thiis-Evensen, E
AU - Biagini, Matteo
AU - Gronbaek, H
AU - Soveri, L M
AU - Olsen, I H
AU - Federspiel, B
AU - Assmus, J
AU - Janson, E T
AU - Knigge, U
PY - 2013
Y1 - 2013
N2 - Background As studies on gastrointestinal neuroendocrine carcinoma (WHO G3) (GI-NEC) are limited, we reviewed clinical data to identify predictive and prognostic markers for advanced GI-NEC patients. Patients and methods Data from advanced GI-NEC patients diagnosed 2000-2009 were retrospectively registered at 12 Nordic hospitals. Results The median survival was 11 months in 252 patients given palliative chemotherapy and 1 month in 53 patients receiving best supportive care (BSC) only. The response rate to first-line chemotherapy was 31% and 33% had stable disease. Ki-67
AB - Background As studies on gastrointestinal neuroendocrine carcinoma (WHO G3) (GI-NEC) are limited, we reviewed clinical data to identify predictive and prognostic markers for advanced GI-NEC patients. Patients and methods Data from advanced GI-NEC patients diagnosed 2000-2009 were retrospectively registered at 12 Nordic hospitals. Results The median survival was 11 months in 252 patients given palliative chemotherapy and 1 month in 53 patients receiving best supportive care (BSC) only. The response rate to first-line chemotherapy was 31% and 33% had stable disease. Ki-67
U2 - 10.1093/annonc/mds276
DO - 10.1093/annonc/mds276
M3 - Journal article
C2 - 22967994
VL - 24
SP - 152
EP - 160
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 1
ER -